068760 - Celltrion Pharm, Inc.

068760 Summary

Biopharma

Stock Price & Overview

₩40,850 +0 (+0.00%) Close · Sep 4, 2026 KST

KOSDAQ | ₩KRW | Close: ₩40,850 ≈ US$29 · Market cap ₩1.8tn (≈ $1.3bn)

068760 Financial Statements

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Revenue	536.4	477.8	388.8	386.0	398.7	233.6	172.7	139.5	129.5	101.6	72.6
Cost of Revenue	372.6	355.8	269.1	273.3	279.5	160.4	109.9	99.8	72.1	60.7	24.8
Gross Profit	163.8	122.0	119.7	112.8	119.3	73.2	62.8	39.6	57.5	40.9	47.8
Selling, General & Administrative	88.8	71.9	71.0	66.4	65.3	44.6	45.0	34.4	48.6	43.2	39.6
Operating Income	56.1	37.2	36.1	38.2	47.8	23.6	15.7	3.7	8.7	-14.9	-12.7
Finance Income	2.9	1.6	1.3	1.1	0.4	0.3	0.3	0.6	0.2	-8.3	-7.3
Finance Costs	6.7	7.5	8.3	6.2	5.4	4.6	5.2	6.0	5.5	0.1	0.0
Pretax Income	49.7	29.8	26.2	30.5	42.5	20.1	10.0	-7.1	2.5	-23.4	-20.1
Income Tax Expense	11.0	7.8	4.9	4.5	7.9	-0.8	0.5	3.1	-0.3	-2.4	-5.5
Net Income	38.8	22.0	21.3	26.0	34.6	20.9	9.5	-10.2	2.8	-21.0	-14.6
Total Comprehensive Income	38.8	22.0	21.3	26.0	34.2	20.6	10.0	-10.0	2.8	-21.0	-14.6

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Assets	759.4	669.5	641.6	599.7	637.9	548.1	471.0	449.7	469.2	441.5	422.8
Current Assets	470.6	391.7	364.8	311.9	331.1	231.0	188.8	196.8	208.7	170.2	148.4
Cash & Cash Equivalents	49.9	45.5	19.7	31.4	80.2	25.7	10.7	6.6	3.9	8.8	9.0
Inventories	122.9	101.4	100.4	69.2	63.9	55.0	33.1	42.0	65.2	65.9	73.7
Trade Receivables	—	—	—	185.8	172.4	140.5	138.8	132.1	122.8	80.4	42.6
Non-current Assets	288.8	277.8	276.8	287.8	306.7	317.1	282.2	252.9	260.5	271.3	274.5
Property, Plant & Equipment	201.6	205.6	216.4	227.8	241.0	247.2	216.0	195.0	199.3	209.3	218.6
Intangible Assets	43.2	39.2	39.3	41.3	39.4	38.1	36.4	30.5	34.5	35.1	33.4
Total Liabilities	323.5	272.5	265.0	242.9	305.9	247.5	190.9	182.1	177.1	166.5	232.3
Current Liabilities	283.6	247.7	249.3	212.0	259.9	184.9	149.1	144.7	124.8	73.5	114.2
Non-current Liabilities	39.9	24.9	15.6	30.9	46.0	62.6	41.8	37.4	52.3	93.0	118.0
Total Equity	436.0	396.9	376.7	356.8	332.0	300.6	280.0	267.6	292.0	275.0	190.6
Share Capital	21.8	20.8	19.8	268.3	266.6	264.9	263.5	310.9	309.7	307.3	196.8
Retained Earnings	170.2	132.5	111.5	91.2	65.8	31.6	9.6	-47.6	-22.5	-37.5	-16.2

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Cash from Operating Activities	86.4	56.6	8.8	-4.0	93.2	36.2	28.4	13.5	-5.0	-26.8	-5.1
Cash from Investing Activities	-57.5	-12.1	-4.2	-14.6	-16.3	-44.9	-32.6	-7.2	-1.1	2.3	-49.0
Purchase of Property, Plant & Equipment	16.2	4.9	5.0	3.9	11.1	42.0	30.5	7.1	1.0	—	—
Cash from Financing Activities	-24.5	-18.7	-16.2	-30.2	-22.4	23.6	8.3	-3.5	1.2	24.3	60.5
Net Change in Cash	4.4	25.8	-11.7	-48.8	54.4	15.0	4.1	2.8	-5.0	—	—

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Revenue	153.3	132.1	154.4	138.2	131.3	112.5	135.6	128.1	117.2	97.0
Cost of Revenue	102.7	92.8	107.4	95.6	90.5	79.1	101.2	94.0	87.5	73.0
Gross Profit	50.6	39.3	47.0	42.6	40.8	33.4	34.3	34.1	29.6	23.9
Selling, General & Administrative	26.9	22.7	24.4	22.2	22.4	19.7	20.3	17.4	17.1	17.2
Operating Income	19.3	12.9	13.7	16.1	15.5	10.7	10.5	13.6	9.4	3.7
Finance Income	0.8	0.8	0.8	0.8	0.7	0.6	0.4	0.4	0.4	0.4
Finance Costs	1.6	1.6	1.6	1.6	1.7	1.8	1.9	1.9	1.8	1.9
Pretax Income	18.5	11.8	10.5	15.1	14.6	9.5	8.1	12.1	7.6	2.0
Income Tax Expense	4.8	3.0	1.6	3.7	3.5	2.2	1.9	3.8	2.0	0.1
Net Income	13.7	8.8	8.9	11.5	11.1	7.3	6.2	8.3	5.6	1.9
Total Comprehensive Income	13.7	8.8	8.9	11.5	11.1	7.3	6.2	8.3	5.6	1.9

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Assets	779.2	768.8	759.4	745.8	728.2	675.9	669.5	652.6	639.8	636.0
Current Assets	493.7	481.6	470.6	464.5	442.0	395.6	391.7	375.8	372.6	362.4
Cash & Cash Equivalents	51.7	56.8	49.9	29.6	29.7	48.1	45.5	28.1	12.2	29.4
Inventories	126.7	126.0	122.9	129.9	120.0	104.7	101.4	124.2	124.5	110.5
Trade Receivables	—	—	—	—	—	—	—	196.6	202.8	197.5
Non-current Assets	285.5	287.2	288.8	281.3	286.2	280.4	277.8	276.8	267.2	273.6
Property, Plant & Equipment	190.0	191.5	201.6	202.5	206.1	205.9	205.6	206.2	209.3	213.1
Intangible Assets	60.8	61.4	43.2	43.5	44.0	40.3	39.2	39.0	39.1	39.1
Total Liabilities	330.0	334.0	323.5	319.4	313.9	273.6	272.5	262.6	258.8	261.4
Current Liabilities	288.0	292.7	283.6	287.6	281.8	246.2	247.7	237.3	248.3	250.5
Non-current Liabilities	42.0	41.3	39.9	31.8	32.1	27.4	24.9	25.3	10.5	10.9
Total Equity	449.2	434.8	436.0	426.4	414.3	402.3	396.9	390.0	381.0	374.6
Share Capital	22.3	22.3	21.8	21.8	21.8	21.8	20.8	272.2	271.9	271.3
Retained Earnings	169.7	156.0	170.2	161.3	149.9	138.8	132.5	126.3	118.0	112.4

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Cash from Operating Activities	-2.6	33.8	7.2	23.4	13.4	42.4	29.8	20.1	-12.0	18.7
Cash from Investing Activities	10.7	-24.8	24.0	-21.4	-27.6	-32.6	-5.8	2.1	-6.6	-1.8
Purchase of Property, Plant & Equipment	3.9	3.1	3.2	2.1	4.4	6.4	1.9	1.1	1.4	0.6
Cash from Financing Activities	-13.1	-2.2	-10.9	-2.1	-4.2	-7.2	-6.6	-6.3	1.5	-7.3
Net Change in Cash	-5.1	6.9	20.3	-0.1	-18.4	2.6	17.4	15.9	-17.1	9.6

Separate / parent-only (OFS) — this company files no consolidated statements, from DART. 11 fiscal years and 10 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

068760 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	536.4	+12.3%	+11.6%	+18.1%	+22.1%
Operating income	56.1	+50.7%	+13.7%	+18.9%	—
Net income	38.8	+76.4%	+14.3%	+13.1%	—
EPS	₩873	+76.4%	+14.3%	+13.1%	—
Operating cash flow	86.4	+52.7%	—	+19.0%	—
Shareholders' equity	436.0	+9.8%	+6.9%	+7.7%	+8.6%

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

068760 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Gross margin	30.5%	25.5%	30.8%	29.2%	29.9%	31.3%
Operating margin	10.5%	7.8%	9.3%	9.9%	12.0%	10.1%
Net margin	7.2%	4.6%	5.5%	6.7%	8.7%	9.0%
Return on equity	9.3%	5.7%	5.8%	7.5%	10.9%	7.2%
Return on assets	5.4%	3.4%	3.4%	4.2%	5.8%	4.1%
Operating cash flow / revenue	16.1%	11.8%	2.3%	-1.0%	23.4%	15.5%
Capex / revenue	3.0%	1.0%	1.3%	1.0%	2.8%	18.0%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 068760

Symbol	Last Price
214370Caregen Co., Ltd.	₩44,500 +1.5%
347850D & D Pharmatech, Inc.	₩49,200 +1.4%
237690ST Pharm Co., Ltd.	₩101,200 +2.2%
226950Olix Pharmaceuticals, Inc.	₩95,900 +4.5%
140410Mezzion Pharma Co., Ltd.	₩65,000 +0.0%
007390Naturecell Co., Ltd.	₩23,950 +0.2%
006280GC Biopharma Corp.	₩127,600 +0.5%
950160Kolon Tissue Gene, Inc.	₩17,100 +1.1%
039200Oscotec, Inc.	₩36,600 +1.9%
069620Daewoong Pharma	₩116,100 +1.1%

Compare all 48 in Biopharma

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.